Moleculight has developed and commercialized a portable point-of-care wound imaging system – with models called the MolecuLight i:X® and DX™ — to detect elevated bacterial loads in wounds and to perform digital measurement of wounds. The devices are FDA/CE/Health Canada approved, have a robust reimbursement pathway in the USA and Korea and have over 60 peer-reviewed publications, including 1,500+ patients, to provide a comprehensive body of clinical evidence supporting the utility of the devices for improving wound care decision-making and patient outcomes. With a direct sales channel in North America and 16 distributors in 18 global markets, MolecuLight is successful on route to become the standard of care for wound care diagnostics.
Anil Amlani
Privacy Policy | © 2024 iGan Partners. All Rights Reserved.